US Pharma MarketingResilience and Lilly to increase US medicines production with $750m investment
Resilience and Lilly have invested $750m to boost production of Lilly’s KwikPen to boost the US supply of diabetes and obesity medicines.
Resilience and Lilly have invested $750m to boost production of Lilly’s KwikPen to boost the US supply of diabetes and obesity medicines.
Source: Pharmaceutical Technology